More News! 4 Nov 2022 Alimentiv and Summit collaborate to tackle liver disease NASH Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit Clinical Research, in a bid to tackle non-alcoholic steatohepatitis (NASH). They announced a strategic alliance to tackle the now growing global epidemic with no approved treatments. It says that current challenges include optimizing and end-point assessment, minimizing screen failures and […] November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 A new weapon against antibiotic-resistant bacteria? Is edoxudine, an anti-herpes molecule discovered in the 60s, effective against Klebsiella pneumoniae, a common bacterium in hospitals? The excessive use of antibiotics has pushed bacteria to develop resistance mechanisms to treatment. Antibiotic resistance is now considered by the WHO as one of the greatest threats to health. The lack of treatment against multi-resistant bacteria […] November 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Nov 2022 Get to know 15 of the best biotech companies in Paris Paris may attract tourist masses, but it also attracts a lot of biotech enthusiasts. In this guide, we explore 15 interesting biotech companies in Paris. Paris is one of the biggest biotech clusters in Europe, with a wide range of applications being developed from drug discovery and medical devices to synthetic biology and green energy. […] November 4, 2022 - 11 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 Novadip Biosciences raises €40M for bone defect treatments Novadip Biosciences has raised an additional €40 million ($39.2 million) in a series B equity round and non-dilutive funding. The clinical-stage biopharma company is developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment. The funding will accelerate the clinical development of two of […] November 4, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022Beyond Biotech podcast 21: CanSinoBIO, HTID, Longevity Science Foundation This week, we have three interviews, and four guests. We chat with Pierre Corneille VP of the HTFC, which is responsible for HealthTech Innovation Days; Sergey Jakimov, co-founder and managing partner of LongeVC and the Longevity Science Foundation’s CEO Lisa Ireland; and Pierre Morgon, executive vice president of CanSinoBIO. We also have our weekly contribution […] November 4, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 Companies with exclusive rights to CRISPR diagnostic methods sign agreement Two companies with sole rights to two CRISPR diagnostic methods in markets outside the U.S. and Greater China have signed a licensing agreement. Sherlock Biosciences announced today (November 3) that it has signed a deal with China-based Tolo Biotech which grants co-exclusive rights to the Cas12 and Cas13 method patents. As the only two companies […] November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Trial and new drug for Tourette Syndrome after $250M after funding round completed A phase 3 clinical trial and the potential commercialization of a new class of drug for patients with Tourette Syndrome have been funded after an upsized and oversubscribed $250 million series D funding round. Emalex Biosciences announced the closing today (November 3) of the round that was led by Bain Capital Life Sciences with participation […] November 3, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 3 Nov 2022 What’s on the horizon for gene editing-based therapies? Gene editing has come far in the past decade. However, the field is still finding its feet regarding challenges such as drug delivery, regulation and competition with first-generation gene therapies. Gene editing is a sizzling hot topic in the biotech industry, powered by advances in genetic tools such as CRISPR, TALENs and zinc-finger nucleases. Gene […] November 3, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 New method to treat diabetic foot ulcers revealed by Biocomposites Ltd Diabetic foot infection costs the UK’s NHS around £900 million ($990 million) a year, bringing severe misery to patients. Usually, systemic antibiotics are routinely given to those with diabetes who are susceptible to infected foot ulcers. Unfortunately, effective treatment can be disrupted by complications by using this treatment due to allergic reactions, antibiotic-resistant organisms, the […] November 3, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Positive results of cancer treatment to be presented at Boston conference Results of a cancer treatment in the treatment of gynecologic and breast cancer are to be presented next week, November 8-12, at the Society for Immunotherapy of Cancer (SITC) conference in Boston. Alderaan Biotechnology is a preclinical biotech company that focuses on monoclonal antibody development. It will be making announcements about the most recent development […] November 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits Rapid test kits that can accurately identify infections related to respiratory syncytial virus (RSV), influenza and Covid-19 can deliver results in 15 minutes. UK-based Virax Biolabs, a biotech company focused on the prevention, detection and diagnosis of viral diseases announced today (November 3) the distribution of a tripe virus antigen rapid test kit has been […] November 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Senescent cells as vaccines against cancer? Cancer cells have a series of features that allow the immune system to identify and attack them. However, these same cells create an environment that blocks immune cells and protects the tumor. This means immune cells cannot reach the cancer cells to remove them. The scientific community has been working to increase the effectiveness of […] November 3, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email